Carlos Gallardo

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

Kohei Shitara, Jaffer A. Ajani, Markus Moehler et al. · Nature · 2022 · 442 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Luis Paz‐Ares, Suresh S. Ramalingam, Tudor–Eliade Ciuleanu et al. · Journal of Thoracic Oncology · 2021 · 322 citations · Full text

Pharmacy, Oncology, Pharmacology +17

First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial

Yelena Y. Janjigian, Jaffer A. Ajani, Markus Moehler et al. · Journal of Clinical Oncology · 2024 · 216 citations · Full text

Medicine, Oncology, Gastrointestinal Oncology +1

KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.

Javier Cortés, David W. Cescon, Hope S. Rugo et al. · Journal of Clinical Oncology · 2020 · 185 citations

Medicine, Oncology, Pharmacology +17

LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC

Javier Cortés, David W. Cescon, Hope S. Rugo et al. · Annals of Oncology · 2021 · 52 citations · Full text

Medicine, Oncology, Pharmacotherapy +11